ORAL-B
Today, on Global Accessibility Awareness Day (GAAD), Oral-B proudly launches the Disability Champions Award Programme as part of its ongoing mission to make oral care more accessible to everybody. In partnership with the iADH, the programme aims to make the dentist office experience across Europe more inclusive and positive for those with disabilities and their caregivers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515281762/en/
Benjamin Binot, P&G Europe Oral Care Senior Vice President, announcing the launch of the Disability Champions Awards Programme and previewing the new iO2 toothbrush at Oral-B’s ‘Championing the Perfect Clean for All’ event in Amsterdam. (Photo: Business Wire)
Over a third (36%) of people with visible and non-visible disabilities feel anxious or frustrated when it comes to visiting the dentist. For instance, individuals with Autism Spectrum Disorder may experience heightened anxiety in unfamiliar environments such as a dental practice, as it disrupts their normal routine. Similarly, a patient with Cerebral Palsy, who may face motor challenges without intellectual disability, might find it difficult to brush their teeth effectively due to limitations in fine motor coordination.
To help overcome this, the Disability Champions Award Programme encourages one member of each dental practice across Europe to become the personal lead to ensure their practice is committed to be more disability positive – because sometimes all it takes is one person to truly make a difference.
By completing the necessary online training and accessibility suggestions devised by iADH and Oral-B (available at https://www.iadh.org/oral-b-iadh-disability-champions/) dental staff who meet the requirements will earn their Disability Champions award. They receive a badge that can be used within their office or on social media to encourage others to become Disability Champions. Their practice will also be visible on Oral-B’s website to make it easier for people with disabilities and their caregivers to find disability positive dental practices near them, and to feel more confident and encouraged about visiting the dentist.
Benjamin Binot, P&G Europe Oral Care Senior Vice President, said: “Last year, we launched The Big Rethink initiative in partnership with iADH to rethink how Oral-B can make oral care more inclusive, accessible, and positive for people with disabilities, their caregivers, and everyone in between. This year, we are making our intention good by driving action amongst dental practitioners with the Disability Champions Awards Programme. With our long-term partners, the iADH, we have devised a programme that is straightforward for dental staff to undertake and promote, and that demonstrates their commitment to raising the standard of oral care for people with disabilities.”
Professor. Pedro Diz Dios, President Elect of iADH, said: “At the iADH, we are about promoting equitable oral care. However, we often find that dental practitioners have pre-conceived notions of what makes their practice inclusive, accessible, and positive for people with disabilities and their caregivers. We want to help dentists rethink how to provide a better service for all and believe that appointing one person in the organization to become a Disability Champion will help drive the right change forward. The hope is that as many dental practices as possible across Europe take part in the Disability Champions Award Programme and make better oral care for all a reality.”
The Disability Champions Awards Programme is being launched at Oral-B’s ‘Championing the Perfect Clean for All’ global event being held in Amsterdam between 15-16th May. Over 100+ media, dental professionals and people with disabilities will learn more about the programme, hear inspiring stories from the latest Disability Champions, and experience first-hand how Oral-B plans to bring a better oral care experience to people with disabilities - at the dentist practice and at home. Indeed, Oral-B is previewing its new Oral-B iO2 toothbrush that will bring its revolutionary iO technology to a wider audience, including people with disabilities.
The iO2 is crafted to effortlessly transition manual toothbrush users to electric toothbrushes by bringing Oral-B’s iO technology to life with one simple touch for a simpler, more intuitive cleaning experience that’s tough on plaque and gentle on gums! The dentist-inspired round brush head surrounds teeth, perfectly adapting to their unique shape, removing 100% more bacterial plaque than regular manual brushes even in hard-to-reach areas of the mouth. The iO2 will also come with a new brush head with Smart Bristles that now fully fade their colour to white, making it easy to know when it's time to change your brush head.
1 The Oral Health & Disability European Study (2022) surveyed 5,000 respondents across UK, France, Germany and Italy
Notes to editor:
- About the research: The Oral Health & Disability European Study (2022) surveyed 5,000 respondents across UK, France, Germany and Italy, and was conducted by Reputation Leaders on behalf of Oral-B
- For more information on The Disability Champions Awards Programme, please visit here. The website offers relevant and helpful content for people with disabilities, their caregivers, and families, as well as the professional community.
- Please contact your local Oral-B press office for more information and on local availability of iO2
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bold®, Braun®, Daz®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Herbal Essences®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, Tampax®, Venus® and Vicks®.
Although headquartered in the US, P&G was founded by an Englishman and an Irishman in 1837, our heritage lives on through the work of Research & Development Centres, Manufacturing Plants and Business sites, across the UK & Ireland.
Beyond our Purpose, Values & Principles, the foundation on which P&G was built and our guiding force for over 180 years, we aspire to be a force for growth so that we can be a force for growth in the communities in which we live and work. Through our citizenship priorities, we want to build a better world for all of us - inside and outside of P&G - free from gender bias, with equal voice and equal representation. Environmental sustainability is embedded into our business, and has been for decades, and we have a strong track record of delivering on our goals in this area. We support communities around the world through our people, our brands and our partners by delivering the comforts of home, health and hygiene.
About Oral-B
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About the International Association for Disability and Oral Health (iADH)
The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, research, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515281762/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
